Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Granules IndiaBOM:532482 -0.48%81 Days Payable is 120.90 as of Jun. 2026, which is 11% above its 10-year median of 109.35. GuruFocus rates BOM:532482 with a GF Score™ of 81/100 and a GF Value™ of ₹637.97 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 926 Drug Manufacturers companies, Granules India ranks better than 70.52% on this metric.
The historical rank and industry rank for Granules India's Days Payable or its related term are showing as below:
BOM:532482'
s Days Payable Range Over the Past 10 Years
Min: 84.89 Med: 109.35 Max: 146.88
Current: 133.81
During the past 13 years, Granules India's highest Days Payable was 146.88. The lowest was 84.89. And the median was 109.35.
BOM:532482's Days Payable is ranked better than 70.52% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs BOM:532482: 133.81
Granules India's Days Payable
declined
from Jun. 2025 (155.87) to Jun. 2026 (120.90).
It may suggest that Granules Indiaaccelerated paying its suppliers.
Granules India Days Payable Related Terms
Granules India Days Payable Historical Data
* Premium members only.
The historical data trend for Granules India's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Granules India's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Granules India Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Granules India's Days Payable distribution charts can be found below:
* The bar in red indicates where Granules India's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Granules India's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Granules India (BOM:532482) has a Days Payable of 120.90 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Granules India and its competitors. This is 11% above median its historical median of 109.35. Over the past decade, Granules India's Days Payable has ranged from 84.89 to 146.88. According to the industry distribution chart, Granules India ranks #273 out of 926 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is Granules India's Days Payable too high?
Granules India's current Days Payable of 120.90 is 11% above median its 10-year median of 109.35. Over the past 10 years, this metric has ranged from a low of 84.89 to a high of 146.88. The Drug Manufacturers industry median Days Payable is 90.22. Granules India's value of 120.90 is 34% above this industry median. Based on the distribution chart, Granules India ranks #273 out of 926 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Granules India has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Granules India's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Granules India ranks #273 out of 926 companies for Days Payable. This puts Granules India in the upper half of its industry. The industry median Days Payable is 90.22. Granules India's value of 120.90 is 34% above this benchmark. Historically, Granules India's own Days Payable has ranged from 84.89 to 146.88 over the past decade. While the company's 10-year median is 109.35 vs. the industry median of 90.22, Granules India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Granules India's current Days Payable of 120.90 is 34% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Granules India and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Granules India's current Days Payable is 120.90, which is 11% above median its own 10-year median of 109.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Granules India stock overvalued right now?
Based on GuruFocus' analysis, Granules India (BOM:532482) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹637.97, compared to a current price of ₹841.65 — trading 31.9% above its estimated fair value. The current Days Payable is 120.90, which is 11% above median its 10-year median of 109.35 and 34% above the Drug Manufacturers industry median of 90.22. Granules India's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Granules India (BOM:532482), the current Days Payable is 120.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Granules India (BOM:532482) Overvalued in 2026?
Based on GuruFocus' analysis, Granules India stock appears to be overvalued.
The current stock price of ₹841.65 is trading 31.9% above its estimated GF Value™ of ₹637.97.
GuruFocus considers Granules India to be Significantly Overvalued.
Key valuation signals for BOM:532482:
Days Payable: 120.90 (11% above median its 10-year median of 109.35)
GF Value™: ₹637.97 vs. price of ₹841.65 (31.9% above fair value)
Industry Position: 34% above the Drug Manufacturers median (#273 of 926)
No single metric tells the full story. See the BOM:532482 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World. The company generates a majority of its revenue from its business outside India.
81GF Score
Get the complete analysis for BOM:532482
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532482 has been successfully added to your 
